Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11256990 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL11243175 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL9700518 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL7594880 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL2576617 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL9698119 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL9699184 | 0.98 | ALDH1A1 (0.44) | ALDH1A1TSHRDNM1EPHX2S1PR2 | |
| SCHEMBL5286753 | 0.91 | — | — | |
| SCHEMBL11680465 | 0.82 | FAAH (0.39) | ALDH1A1TSHREPHX2 | |
| SCHEMBL11046710 | 0.81 | EPHX2 (0.62) | ALDH1A1TSHRDNM1EPHX2S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-7270801-B2 | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20040191844-A1 | Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. (US) | 2004-09-30 | — | — | US | disclosed |
| US-6759207-B2 | REPORTER COMPOUND FOR USE IN THE DIAGNOSIS, DETECTION AND TREATMENT OF CANCER | CYTOVIA, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20020150885-A1 | Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof | CYTOVIA, INC. | 2002-10-17 | — | — | US | disclosed |
| US-6342611-B1 | BLOCKED RHODAMINE DERIVATIVES | CYTOVIA, INC. | 2002-01-29 | — | — | US | disclosed |
| US-6335429-B1 | COMPOUND INCLUDING SUBSTRATE FOR ENZYME AND RHODAMINE DYE; DRUG SCREENING FOR ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2002-01-01 | — | — | US | disclosed |
| CN-1281346-A | Novel fluorescent reporter molecules and their applications, including assays for caspases | CYTOVIA INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-4053298-A | HERBICIDAL COMPOSITIONS CONTAINING 1-THIADIAZOLYL-6-CARBAMOYLOXYTETRAHYDROPYRIMIDINONES AND METHODS THEREFOR | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-3951976-A | 1-Thiadiazoly-6-carbamoyloxytetrahydropyrimidinones | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | ALDH1A1 893/4885TSHR 4762/4885DNM1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.